303143
Family Planning in Romania: An Update after Five Years of Donors' Withdrawal
Methods: Trends in maternal mortality, contraceptive use, induced abortion, fertility rate and budget allocations for the national program were analyzed to examine whether changes achieved during the program persisted beyond donors’ withdrawal in 2007. Data on contraceptive use are from DHS surveys 1999 & 2004 and later sub-national survey. Abortion data sources from routine national statistics. Budget allocation information was collected from MOH.
Results: By the end of 2007, the national FP program ensured a “safety net” addressing women’s FP needs at all main entry points to the system. Six years after donors’ withdrawal, changes remain. Statistics demonstrate a decline of abortion ratio from 2.33-abortions/live birth (1993) to 1.11 in 1999, 0.88 in 2004, and eventually to 0.55 abortions/live birth in 2011, while fertility rate remained constant since 1999 (1.3 children/woman). Recent evidence suggests increasing use of modern contraception.
The MOH allocations for contraceptives procurement steadily increased from US$100,000 in 2001 to over US$1.7 million in 2006, and US$2.56M in 2013. By 2014, eligible population has free access to MOH-procured contraceptives and FP services, regardless their health insurance status.
Learning Areas:
Administer health education strategies, interventions and programsConduct evaluation related to programs, research, and other areas of practice
Systems thinking models (conceptual and theoretical models), applications related to public health
Learning Objectives:
Identify donor's interventions to sustain positive changes;
Demonstrate the key role of strengthen the health system to maintain services;
Analyze the importance of the private sector to ensure commodity security.
Keyword(s): Family Planning, Abortion
Qualified on the content I am responsible for because: I was the Technical Director of the project 2001-2008
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.